MOLECULAR IMAGING MARKET ANALYSIS

Molecular Imaging Market, By Product Type (Devices (Molecular Ultrasound Imaging, Positron Emission Tomography (PET), Single Photon Emission Computed Tomography (SPECT), Nuclear Magnetic Resonance (NMR) Spectrometer, Hybrid Products ( Positron Emission Tomography - Computed Tomography (PET-CT), Positron Emission Tomography- Magnetic Resonance (PET-MR), Single Photon Emission Computed Tomography - Computed Tomography (SPECT-CT), Single Photon Emission Computed Tomography - Magnetic Resonance (SPECT-MR)), Software Platforms (On Premises Solutions, Cloud Based Solutions)), By Application (Cardiovascular, Neurology, Oncology, Respiratory, Gastrointestinal, Others Application), By End User (Hospitals, Diagnostic Imaging Centers, Ambulatory Surgical Centers), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Oct 2023
Code : CMI2191
Pages :180
Formats :
Excel and PDF
Industry : Medical Imaging

Leading Companies

Global Molecular Imaging Market- Regional Analysis

Among regions, North America is estimated to hold a dominant position in the global molecular imaging market over the forecast period. North America is estimated to hold 33.5 % of the market share in 2023. The global molecular imaging market is expected to witness significant growth in the coming years, due to increasing inorganic growth strategies, such as acquisitions by key market players. For instance, on February 6, 2023, Lantheus, a U.S.-based manufacturer of medical imaging products, announced it had acquired Cerveau Technologies, Inc. a U.S. based medical technology company. Cerveau’s asset is MK-6240, a second-generation F 18-labeled positron emission tomography (“PET”) imaging agent that targets Tau tangles in Alzheimer’s disease.